card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis

Home / Insights / Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis

Multiple peer-reviewed publications have consistently demonstrated a set of blood-based protein biomarkers associated with idiopathic pulmonary fibrosis (IPF) disease progression. A set of well-qualified assays suitable for use as prognostic or predictive biomarkers within the context for IPF clinical trials is lacking. In collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC), Rules-Based Medicine, a IQVIA Laboratories Company, developed highly optimized and analytically validated blood-based proteomic assays for IPF on the Luminex® multi-analyte profile (MAP), specifically focusing on the most relevant IPF biomarkers related to epithelial damage, fibrosis, inflammation and thrombosis.

 

Complete the form to access this whitepaper